Paris-based Ipsen inked a licensing deal with Sweden’s IRLAB for mesdopetam, a potential drug for Parkinson’s disease.

Shares of Acadia Pharmaceuticals were up nearly 70 percent after a Phase III psychosis trial was halted early as the Parkinson’s disease drug Nuplazid hit primary endpoints, positioning the company to seek another potential regulatory approval.

Acadia Pharmaceuticals Inc. announced that the FDA completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of Nuplazid (pimavanserin) for patients with Parkinson’s disease psychosis.